Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting
  • CME

Amy E. DeZern, MD, MHS
Srdan Verstovsek, MD, PhD
Released: February 16, 2021
Back Next

References

  1. Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130:1125-1131.
  2. Wang X, Hu CS, Petersen B, et al. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv. 2018;2:2378-2388.
  3. Mascarenhas J, Komrokji RS, Cavo M, et al. Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to Janus Kinase inhibitor therapy: results of a phase 2 randomized study of two dose levels. Program and abstracts of the 2018 American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego, California. Abstract 685.
  4. Mascarenhas J, Komrokji R, Cavo M, et al. Favorable overall survival with imetelstat treatment correlates with other clinical benefits in intermediate 2 or high-risk myelofibrosis relapsed/refractory to Janus kinase inhibitor. Program and abstracts of the 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 53.
  5. Kleppe M, Koche R, Zou L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33:29-43.
  6. Mertz JA, Keller PJ, Meyer RD, et al. The BET inhibitor, CPI-0610, promotes myeloid differentiation in myelofibrosis patient bone marrow and peripheral CD34+ hematopoietic stem cells. Program and abstracts of the 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 3079.
  7. Mascarenhas J, Harrison C, Patriarca A, et al. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naïve myelofibrosis patients: update of MANIFEST phase 2 study. ASH 2020. Program and abstracts of the 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 55.
  8. Verstovsek S, Mascarenhas H, Kremyanskaya M, et al. CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as “add-on” to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: update of MANIFEST phase 2 study. Program and abstracts of the 2020 European Hematology Association Annual Meeting; June 11-21, 2020. Abstract 56.
  9. ClinicalTrials.gov. A phase 2 study of CPI-0610 with and without ruxolitinib in patients with myelofibrosis. Available at: https://clinicaltrials.gov/ct2/show/NCT02158858. Accessed February 10, 2021.
  10. Bechter O, Schoffski P. Make your best BET: the emerging role of BET inhibitor treatment in malignant tumors. Pharmacol Ther. 2020;208:107479.
  11. Mesa RA, Kiladjian J-J, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017;35:3844-3850.
  12. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799-807.
  13. Harrison CN, Vannucchi AM, Kiladjian J-J, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701-1707.
  14. Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31:1285-1292.
  15. Naymagon L, Mascarenhas J. Myelofibrosis-related anemia: current and emerging therapeutic strategies. Hemasphere. 2017;1:e1.
  16. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89:766-770.
  17. Suragani RNVS, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20:408-414.
  18. Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2020;382:1219-1231.
  19. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140-151.
  20. Luspatercept [package insert]. Summit, NJ: Celgene Corporation; 2019.
  21. Gerds AT, Vannucchi A, Passamonti F, et al. Duration of response to luspatercept in patients (Pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF): updated data from the phase 2 ACE-536-MF-001 study. Program and abstracts of the 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 2992.
  22. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196-e208.
  23. Gisslinger H, Klade C, Georgiev P, et al. Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension. Program and abstracts of the 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 481.
  24. Abel GA, Kim HT, Hantel A, et al. Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2020;[Epub ahead of print].
  25. Atallah E, Logan B, Chen M, et al. Comparison of patient age groups in transplantation for myelodysplastic syndrome: the Medicare Coverage With Evidence Development study. JAMA Oncol. 2020;6:486-493.
  26. Nakamura R, Saber W, Martens MJ, et al. A multi-center biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50-75 with advanced myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. Program and abstracts of the 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 75.
  27. Sekeres MA, Watts JM, Radinoff A, et al. Efficacy and safety of pevonedistat plus azacitidine vs azacitidine alone in higher-risk myelodysplastic syndromes (MDS) from study P-2001 (NCT02610777). Program and abstracts of the 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 653.
  28. Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell. 2010;37:102-111.
  29. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732-736.
  30. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res. 2009;15:3912-3916.
  31. Smith PG, Traore T, Grossman S, et al. Azacitidine/decitabine synergism with the NEDD8-activating enzyme inhibitor MLN4924 in pre-clinical AML models. Program and abstracts of the 2011 American Society of Hematology Annual Meeting; December 10-13, 2011; San Diego, California. Abstract 578.
  32. Ades L, Watts JM, Radinoff A, et al. Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777). Program and abstracts of the 2020 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2020. Abstract 7506.
  33. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454-2465.
  34. Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30:2214-2220.
  35. ClinicalTrials.gov. Pevonedistat plus azacitidine versus single-agent azacitidine as first-line treatment for participants with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (AML) (PANTHER). Available at: https://clinicaltrials.gov/ct2/show/NCT03268954. Accessed February 10, 2021.
  36. Itzykson R, Santini V, Chaffaut C, et al. Decitabine versus hydroxyurea for advanced proliferative CMML: results of the Emsco randomized phase 3 Dacota trial. Program and abstracts of the 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 654.
  37. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
  38. Loghavi S, Sui D, Wei P, et al. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv. 2018;2:1807-1816.
  39. Wattel E, Guerci A, Hecquet B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood. 1996;88:2480-2487.
  40. Coston T, Pophali P, Vallapureddy R, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019;94:767-779.
  41. Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118:3824-3831.
  42. Santini V, Allione B, Zini G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018;32:413-418.
  43. Bennett JM, Cazzola M, deCastro C, et al. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:858-861.
  44. Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kid Dis. 2016;67:912-924.
  45. Henry DH, Glaspy J, Harrup RA, et al. Oral roxadustat demonstrates efficacy in anemia secondary to lower-risk myelodysplastic syndrome irrespective of ring sideroblasts and baseline erythropoietin levels. Program and abstracts of the 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 1277.
  46. ClinicalTrials.gov. Efficacy and safety of FG-4592 for treatment of anemia in patients with lower risk MDS with low red blood cell transfusion burden. Available at: https://clinicaltrials.gov/ct2/show/NCT03263091. Accessed February 10, 2021.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue